Author

Taufik Momin

Institution: Zydus Lifesciences Limited (India)

Observed institutions: Zydus Lifesciences Limited (India), Zydus Therapeutics Inc. (United States)

ORCID: 0000-0002-6258-6559

Observed ORCID: 0000-0002-6258-6559

OpenAlex ID: A5028794905

Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India

2021 · Taufik Momin, Kevinkumar Kansagra, et al. · EClinicalMedicine · 186

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose)

2022 · Deven V. Parmar, Kevinkumar A. Kansagra, et al. · Clinical Pharmacology in Drug Development · 94

Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis

2023 · Mohammad Shadab Siddiqui, Deven Parmar, et al. · Clinical Gastroenterology and Hepatology · 47

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZY‐IL1 in Three Patients with Cryopyrin‐Associated Periodic Syndromes

2023 · Pravin Hissaria, Kevinkumar Kansagra, et al. · Clinical Pharmacology in Drug Development · 32

Pharmacokinetic, Safety, and Pharmacodynamic Profiles of Saroglitazar Magnesium in Cholestatic Cirrhosis With Hepatic Impairment and Participants With Renal Impairment

2024 · Raj Vuppalanchi, Mary M. Cruz, et al. · Clinical Pharmacology & Therapeutics · 10

Pharmacokinetics and Safety Evaluation of Single‐Dose Saroglitazar Magnesium in Subjects with Hepatic Impairment

2023 · Eric Lawitz, Deven Parmar, et al. · Clinical Pharmacology in Drug Development · 2

Estimation of ZYKR1 in human urine and plasma utilizing LC-MS/MS positive electrospray ionization; a kappa opioid receptor (KOR) agonist

2021 · Ashok Ghoghari, Chandrakant Bhatt, et al. · Journal of Chromatography B · 2

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel kappa opioid receptor agonist ZYKR1: a randomized double-blind placebo-control phase 1 study in healthy adult human participants

2023 · Kevinkumar A. Kansagra, Taufik Momin, et al. · Naunyn-Schmiedeberg s Archives of Pharmacology · 1

A Food‐Effect Study to Evaluate the Oral Bioavailability of Desidustat

2022 · Hardik Patel, Taufik Momin, et al. · Clinical Pharmacology in Drug Development · 1

A phase 2b/3 trial of saroglitazar in primary biliary cholangitis

2026 · Raj Vuppalanchi, Alejandra Villamil, et al. · Hepatology

Saroglitazar improves hepatic steatosis and liver enzymes in women with polycystic ovary syndrome and MASLD: A multicenter, double-blind, placebo-controlled study

2026 · Niharika Samala, José González-González, et al. · Hepatology

SAT-668 Saroglitazar Improves Hepatic Steatosis And Liver Enzymes In Women With PCOS And MASLD: Results Of Evidences VII Randomized Control Study

2025 · Deven Parmar, Niharika Samala, et al. · Journal of the Endocrine Society

Metabolic Flexibility Predicts Response to Saroglitazar in Liver Transplant Recipients With Metabolic Dysfunction–associated Steatotic Liver Disease

2025 · Kavin Parmar, Anh Tuan Bui, et al. · Transplantation

Works count: 13

Citation count: 375

H-index: 5

I10-index: 5